CER - Central Repository
Institute of Chemistry, Technology and Metallurgy
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrillic)
    • Serbian (Latin)
  • Login
View Item 
  •   CER
  • IHTM
  • Radovi istraživača / Researchers' publications
  • View Item
  •   CER
  • IHTM
  • Radovi istraživača / Researchers' publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Antidiabetics: Structural Diversity of Molecules with a Common Aim

No Thumbnail
Authors
Popović-Đorđević, Jelena B.
Jevtić, Ivana
Stanojković, Tatjana
Article (Published version)
Metadata
Show full item record
Abstract
Background: Diabetes mellitus type 2 (DMT2) is an endocrine disease of global proportions which is currently affecting 1 in 12 adults in the world, with still increasing prevalence. World Health Organization (WHO) declared this worldwide health problem, as an epidemic disease, to be the only non-infectious disease with such categorization. People with DMT2 are at increased risk of various complications and have shorter life expectancy. The main classes of oral antidiabetic drugs accessible today for DMT2 vary in their chemical composition, modes of action, safety profiles and tolerability. Methods: A systematic search of peer-reviewed scientific literature and public databases has been conducted. We included the most recent relevant research papers and data in respect to the focus of the present review. The quality of retrieved papers was assessed using standard tools. Results: The review highlights the chemical structural diversity of the molecules that have the common target-DMT2. So...-called traditional antidiabetics as well as the newest and the least explored drugs include polypeptides and amino acid derivatives (insulin, glucagon-like peptide 1, dipeptidyl peptidase-IV inhibitors, amylin), sulfonylurea derivatives, benzylthiazolidine-2,4-diones (peroxisome proliferator activated receptor-gamma agonists/glitazones), condensed guanido core (metformin) and sugar-like molecules (alpha-glucosidase and sodium/glucose co-transporter 2 inhibitors). Conclusion: As diabetes becomes a more common disease, interest in new pharmacological targets is on the rise.

Keywords:
DMT2 / peroxisome proliferator activated receptor-gamma agonists / metformin / alpha-glucosidase inhibitors / glucagon-likepeptide 1 analogues / dipeptidyl peptidase-IV inhibitors / amylin analogues / sodium
Source:
Current Medicinal Chemistry, 2018, 25, 18, 2140-2165
Publisher:
  • Bentham Science Publ Ltd, Sharjah
Funding / projects:
  • Structure-activity relationship of newly synthesized biological active compound (RS-172032)

DOI: 10.2174/0929867325666171205145309

ISSN: 0929-8673

PubMed: 29210642

WoS: 000433035000006

Scopus: 2-s2.0-85048869485
[ Google Scholar ]
9
7
URI
https://cer.ihtm.bg.ac.rs/handle/123456789/2315
Collections
  • Radovi istraživača / Researchers' publications
Institution/Community
IHTM
TY  - JOUR
AU  - Popović-Đorđević, Jelena B.
AU  - Jevtić, Ivana
AU  - Stanojković, Tatjana
PY  - 2018
UR  - https://cer.ihtm.bg.ac.rs/handle/123456789/2315
AB  - Background: Diabetes mellitus type 2 (DMT2) is an endocrine disease of global proportions which is currently affecting 1 in 12 adults in the world, with still increasing prevalence. World Health Organization (WHO) declared this worldwide health problem, as an epidemic disease, to be the only non-infectious disease with such categorization. People with DMT2 are at increased risk of various complications and have shorter life expectancy. The main classes of oral antidiabetic drugs accessible today for DMT2 vary in their chemical composition, modes of action, safety profiles and tolerability. Methods: A systematic search of peer-reviewed scientific literature and public databases has been conducted. We included the most recent relevant research papers and data in respect to the focus of the present review. The quality of retrieved papers was assessed using standard tools. Results: The review highlights the chemical structural diversity of the molecules that have the common target-DMT2. So-called traditional antidiabetics as well as the newest and the least explored drugs include polypeptides and amino acid derivatives (insulin, glucagon-like peptide 1, dipeptidyl peptidase-IV inhibitors, amylin), sulfonylurea derivatives, benzylthiazolidine-2,4-diones (peroxisome proliferator activated receptor-gamma agonists/glitazones), condensed guanido core (metformin) and sugar-like molecules (alpha-glucosidase and sodium/glucose co-transporter 2 inhibitors). Conclusion: As diabetes becomes a more common disease, interest in new pharmacological targets is on the rise.
PB  - Bentham Science Publ Ltd, Sharjah
T2  - Current Medicinal Chemistry
T1  - Antidiabetics: Structural Diversity of Molecules with a Common Aim
VL  - 25
IS  - 18
SP  - 2140
EP  - 2165
DO  - 10.2174/0929867325666171205145309
ER  - 
@article{
author = "Popović-Đorđević, Jelena B. and Jevtić, Ivana and Stanojković, Tatjana",
year = "2018",
abstract = "Background: Diabetes mellitus type 2 (DMT2) is an endocrine disease of global proportions which is currently affecting 1 in 12 adults in the world, with still increasing prevalence. World Health Organization (WHO) declared this worldwide health problem, as an epidemic disease, to be the only non-infectious disease with such categorization. People with DMT2 are at increased risk of various complications and have shorter life expectancy. The main classes of oral antidiabetic drugs accessible today for DMT2 vary in their chemical composition, modes of action, safety profiles and tolerability. Methods: A systematic search of peer-reviewed scientific literature and public databases has been conducted. We included the most recent relevant research papers and data in respect to the focus of the present review. The quality of retrieved papers was assessed using standard tools. Results: The review highlights the chemical structural diversity of the molecules that have the common target-DMT2. So-called traditional antidiabetics as well as the newest and the least explored drugs include polypeptides and amino acid derivatives (insulin, glucagon-like peptide 1, dipeptidyl peptidase-IV inhibitors, amylin), sulfonylurea derivatives, benzylthiazolidine-2,4-diones (peroxisome proliferator activated receptor-gamma agonists/glitazones), condensed guanido core (metformin) and sugar-like molecules (alpha-glucosidase and sodium/glucose co-transporter 2 inhibitors). Conclusion: As diabetes becomes a more common disease, interest in new pharmacological targets is on the rise.",
publisher = "Bentham Science Publ Ltd, Sharjah",
journal = "Current Medicinal Chemistry",
title = "Antidiabetics: Structural Diversity of Molecules with a Common Aim",
volume = "25",
number = "18",
pages = "2140-2165",
doi = "10.2174/0929867325666171205145309"
}
Popović-Đorđević, J. B., Jevtić, I.,& Stanojković, T.. (2018). Antidiabetics: Structural Diversity of Molecules with a Common Aim. in Current Medicinal Chemistry
Bentham Science Publ Ltd, Sharjah., 25(18), 2140-2165.
https://doi.org/10.2174/0929867325666171205145309
Popović-Đorđević JB, Jevtić I, Stanojković T. Antidiabetics: Structural Diversity of Molecules with a Common Aim. in Current Medicinal Chemistry. 2018;25(18):2140-2165.
doi:10.2174/0929867325666171205145309 .
Popović-Đorđević, Jelena B., Jevtić, Ivana, Stanojković, Tatjana, "Antidiabetics: Structural Diversity of Molecules with a Common Aim" in Current Medicinal Chemistry, 25, no. 18 (2018):2140-2165,
https://doi.org/10.2174/0929867325666171205145309 . .

DSpace software copyright © 2002-2015  DuraSpace
About CeR – Central Repository | Send Feedback

re3dataOpenAIRERCUB
 

 

All of DSpaceInstitutions/communitiesAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About CeR – Central Repository | Send Feedback

re3dataOpenAIRERCUB